Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Growth in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 3,516,000 shares, a growth of 17.1% from the October 31st total of 3,001,500 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is presently 11,720.0 days.

Innovent Biologics Price Performance

OTCMKTS:IVBXF remained flat at $4.85 on Monday. The company has a fifty day moving average of $5.37 and a two-hundred day moving average of $5.17. Innovent Biologics has a 52-week low of $3.83 and a 52-week high of $6.40.

Innovent Biologics Company Profile

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.